"Erlotinib Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER.
| Descriptor ID |
D000069347
|
| MeSH Number(s) |
D03.633.100.786.375
|
| Concept/Terms |
CP 358774- CP 358774
- 358774, CP
- CP 358,774
- 358,774, CP
- CP-358,774
- CP358,774
- CP-358774
- CP358774
Erlotinib- Erlotinib
- N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
|
Below are MeSH descriptors whose meaning is more general than "Erlotinib Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Erlotinib Hydrochloride".
This graph shows the total number of publications written about "Erlotinib Hydrochloride" by people in this website by year, and whether "Erlotinib Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 7 | 7 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 5 | 5 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 2 | 2 |
| 2015 | 3 | 3 | 6 |
| 2016 | 3 | 1 | 4 |
| 2017 | 1 | 4 | 5 |
| 2018 | 0 | 3 | 3 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 1 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Erlotinib Hydrochloride" by people in Profiles.
-
Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer. N Engl J Med. 2025 Jun 19; 392(23):2346-2356.
-
BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C-MYC/PLCG1/Perk Axis. Adv Sci (Weinh). 2023 12; 10(34):e2303091.
-
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 02 10; 41(5):1105-1115.
-
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. J Thorac Oncol. 2022 09; 17(9):1086-1097.
-
Profound effects of gastric secretion rate variations on the precipitation of erlotinib in duodenum - An in vitro investigation. Int J Pharm. 2022 May 10; 619:121722.
-
EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer. Theranostics. 2021; 11(13):6632-6643.
-
Synthesis, Tumor Specificity, and Photosensitizing Efficacy of Erlotinib-Conjugated Chlorins and Bacteriochlorins: Identification of a Highly Effective Candidate for Photodynamic Therapy of Cancer. J Med Chem. 2021 01 14; 64(1):741-767.
-
Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database. JAMA Netw Open. 2020 03 02; 3(3):e200452.
-
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. Clin Lung Cancer. 2020 05; 21(3):232-237.
-
Perioperative Gemcitabine?+?Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol. 2019 Dec; 26(13):4489-4497.